MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Massot, O.
Right arrow Articles by Fillion, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Massot, O.
Right arrow Articles by Fillion, G.

5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5- hydroxytryptamine1B/1D receptors

O Massot, JC Rousselle, MP Fillion, B Grimaldi, I Cloez-Tayarani, A Fugelli, N Prudhomme, L Seguin, B Rousseau, M Plantefol, R Hen and G Fillion

Unite de Pharmacologie Neuro-Immuno-Endocrinlenne, Institut Pasteur, Paris, France.

The serotonergic system controls the activity of neurotransmissions involved in numerous physiological functions. It is also thought to be crucially implicated in various pathologies, including psychiatric disorders such as depression, anxiety, and aggressiveness. The properties of 5-hydroxytryptamine (5-HT)-moduline, a novel endogenous peptide, have been tested in vitro and in vivo. Binding studies have shown that the peptide specifically interacts with 5-HT1B/1D receptors via a noncompetitive mechanism corresponding to a high apparent affinity (EC50 = 10(10) M). The interaction was shown in rat and guinea pig brain tissues and in cells transfected with either 5-HT1B or 5-HT1D beta receptor gene. [3H]5-HT-moduline binds to a single population of sites in mammalian brain (Kd = 0.4 nM in rat, Kd = 0.8 nM in guinea pig) as well as in transfected cells expressing the 5-HT1B or the 5- HT1D beta receptors (Kd = 0.2 and 0.6 nM, respectively). Furthermore, the binding is clearly specific of the LSAL sequence. Autoradiographic studies showed an heterogeneous brain distribution of this site. The interaction of 5-HT-moduline with the 5-HT1B/1D receptor corresponds to a decrease in the functional activity of the receptor (i.e., a decrease in the inhibitory effect of a 5-HT1B agonist on the evoked release of [3H]5-HT from synaptosomal preparation). It was also shown that 5-HT- moduline possess an in vivo effect in the social interaction test in mouse. Finally, it was demonstrated that 5-HT-moduline was released from brain synaptosomal preparation by a K+/Ca(2+)-dependent mechanism. In conclusion, 5-HT-moduline is a novel endogenous peptide regulating the serotonergic activity via a direct action at presynaptic 5-HT receptor. It may play an important role in the physiological mechanisms involving the serotonergic system, particularly in mechanisms corresponding to the elaboration of an appropriate response of the central nervous system to a given stimulus.

Volume 50, Issue 4, pp. 752-762, 10/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
K. B. Fink and M. Gothert
5-HT Receptor Regulation of Neurotransmitter Release
Pharmacol. Rev., December 1, 2007; 59(4): 360 - 417.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Watson, S. Jenkinson, W. Kazmierski, and T. Kenakin
The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor
Mol. Pharmacol., April 1, 2005; 67(4): 1268 - 1282.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Christopoulos and T. Kenakin
G Protein-Coupled Receptor Allosterism and Complexing
Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. Varney, N. D. P. Cosford, C. Jachec, S. P. Rao, A. Sacaan, F.-F. Lin, L. Bleicher, E. M. Santori, P. J. Flor, H. Allgeier, et al.
SIB-1757 and SIB-1893: Selective, Noncompetitive Antagonists of Metabotropic Glutamate Receptor Type 5
J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 170 - 181.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
S. Lazareno, P. Gharagozloo, D. Kuonen, A. Popham, and N. J. M. Birdsall
Subtype-Selective Positive Cooperative Interactions between Brucine Analogues and Acetylcholine at Muscarinic Receptors: Radioligand Binding Studies
Mol. Pharmacol., March 1, 1998; 53(3): 573 - 589.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
I. Cloez-Tayarani, A. Cardona, J.-C. Rousselle, O. Massot, L. Edelman, and G. Fillion
Autoradiographic characterization of [3H]-5-HT-moduline binding sites in rodent brain and their relationship to 5-HT1B receptors
PNAS, September 2, 1997; 94(18): 9899 - 9904.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
D. Bagnol, X.-Y. Lu, C. B. Kaelin, H. E. W. Day, M. Ollmann, I. Gantz, H. Akil, G. S. Barsh, and S. J. Watson
Anatomy of an Endogenous Antagonist: Relationship between Agouti-Related Protein and Proopiomelanocortin in Brain
J. Neurosci., September 15, 1999; 19(18): RC26 - RC26.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1996 by the American Society for Pharmacology and Experimental Therapeutics